{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:15:35Z","timestamp":1771539335292,"version":"3.50.1"},"reference-count":0,"publisher":"Pensoft Publishers","issue":"1","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p><jats:bold>Introduction: <\/jats:bold>The European League Against Rheumatism updates the recommendations for managing rheumatoid arthritis. Again, it is not specified which DAS28 is there in view (with erythrocyte sedimentation rate or C-reactive protein).<\/jats:p>\n          <jats:p>&amp;nbsp;<\/jats:p>\n          <jats:p><jats:bold>Aim:<\/jats:bold> The aim of the study is to check whether Disease Activity Score-28 (erythrocyte sedimentation rate) and Disease Activity Score-28 (C-reactive protein) represent equally the activity of rheumatoid arthritis in the course of treatment with biological agents.<\/jats:p>\n          <jats:p>&amp;nbsp;<\/jats:p>\n          <jats:p><jats:bold>Materials and methods:<\/jats:bold> In a retrospective study we analyzed the database of real clinical practice over a 12-month period of biological treatment of rheumatoid arthritis. Disease Activity Score-28 (erythrocyte sedimentation rate) and (C-reactive protein) are compared at the start and at the end of the study.<\/jats:p>\n          <jats:p>&amp;nbsp;<\/jats:p>\n          <jats:p><jats:bold>Results: <\/jats:bold>The mean difference between the two variants of disease activity scores at baseline and at the end of the study is significant (p &lt; 0.001). The Disease Activity Score-28 (erythrocyte sedimentation rate) represents a remarkably small proportion of patients with remission and low activity (&lt;3.2) at baseline (18.46%) and at the end of the study (40.51%). Disease Activity Score-28 (C-reactive protein) represents a significantly high proportion of patients in remission and low activity (&lt;3.2) at the end of the study (69.74%). Estimates of activity according to the two variants show significant discrepancy between each other and low level of agreement (kappa = 0.235-0.464). Discrepancies are not related to the type of biological drug (anti-TNF or not).<\/jats:p>\n          <jats:p>&amp;nbsp;<\/jats:p>\n          <jats:p><jats:bold>Conclusion:<\/jats:bold> The two DAS28 variants are not interchangeable with the same threshold for low activity in measuring the response to biological therapy.<\/jats:p>","DOI":"10.3897\/folmed.62.e47714","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T17:11:43Z","timestamp":1585674703000},"page":"46-51","source":"Crossref","is-referenced-by-count":3,"title":["DAS28-ESR and DAS28-CRP - are they Interchangeable in Measuring the Activity of Rheumatoid Arthritis in Response to Treatment with Biological Agents?"],"prefix":"10.3897","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-4100","authenticated-orcid":true,"given":"Tanya K.","family":"Shivacheva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2258","published-online":{"date-parts":[[2020,3,31]]},"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/47714\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/47714\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=47714&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T17:11:43Z","timestamp":1585674703000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/47714\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,31]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.62.e47714","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"value":"1314-2143","type":"electronic"},{"value":"0204-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}